Flaxseed lignans found to influence gut microbiome and breast cancer risk

Mer­ck’s block­buster can­cer drug Keytru­da made $18.4 bil­lion in the first nine months of the year — near­ly the same amount as the re­port­ed rev­enue

In­ma­gene Bio­phar­ma­ceu­ti­cals, a biotech de­vel­op­ing im­munol­o­gy treat­ments, will take over the Nas­daq list­ing of Ike­na On­col­o­gy in a re­verse merg­er that ends the tar­get com­pa­ny’